MatriStem for diabetic foot ulcers

Press Release: ACell Initiates Post-Market Comparative Study of MatriStem® versus Dermagraft® in Patients with Diabetic Foot Ulcers Quote: ACell, Inc., a leading regenerative medicine company focused on the development, manufacturing and commercialization of tissue repair products, today announced it has initiated, with multiple patients enrolled, a U.S. post-market clinical trial (NCT01858545) comparing the efficacy of MatriStem® to a leading cellular scaffold, Dermagraft®, for the treatment of patients with diabetic foot ulcers (DFUs) that failed to adequately heal following initial standard of care therapy

Original post:
MatriStem for diabetic foot ulcers

Previous post:

Next post: